STAAR Surgical Generates $464,000 in Cash from Operations During Thi...(Basic and diluted ...),Health

Date:11/2/2009

Basic and diluted $(0.06) $(0.08) ====== ====== Weighted average shares outstanding: Basic and diluted 34,701 29,490 ====== ====== Nine Months Ended ----------------- October 2, September 26, 2009 2008 ---- ---- Net sales 100.0% $55,514 100.0% $56,737 Cost of sales 44.4% 24,675 47.6% 26,990 ------ ------ Gross profit 55.6% 30,839 52.4% 29,747 ------ ------ Selling, general and administrative expenses: General and administrative 20.9% 11,626 20.2% 11,441 Marketing and selling 32.0% 17,784 36.4% 20,627 Research and development 7.9% 4,395 10.5% 5,965 Loss on settlement of pre-existing distribution arrangement 0.0% - 6.8% 3,850 --- ----- Total selling, general and administrative expenses: 60.9% 33,805 73.8% 41,883 ------ ------ Operating loss -5.3% (2,966) -21.4% (12,136) ------ ------- Other income (expense): Interest income 0.1% 36 0.2% 138 Interest expense
'/>"/>

SOURCE STAAR Surgical Company Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
Related medicine technology :

1. STAAR Surgical to Present at the 20th Annual Oppenheimer Healthcare Conference in New York
2. STAAR Surgical Announces Third Quarter 2009 Earnings Release Date and Conference Call
3. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
4. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
5. Portrait(R) Plasma - A New Non-Surgical Option for one of the Most Requested Aesthetic Treatment - Aging Eyes
6. New Non-Surgical Stem-Cell Procedure to Relieve Chronic Tendon Problems
7. Ceremeds OSTENE(R) Stops Bone Bleeding Without Added Risk of Surgical Infection, New Study Finds
8. Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
9. Anesiva Commences Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Bunionectomy
10. Anesiva Announces Pivotal Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Total Knee Replacement
11. PEAK Surgical Announces Positive Results From Preclinical Study of PEAK PlasmaBlade(TM) for Obstetric and Gynecologic Surgery